


Active Filter(s):
Details:
The trial will assess the safety of the treatment and the potential initial efficacy of the BioSphincter (Autologous Bioengineered Internal Anal Sphincter) in reducing the number of incontinence episodes in patients with severe fecal incontinence.
Lead Product(s): Autologous Bioengineered Internal Anal Sphincter
Therapeutic Area: Gastroenterology Product Name: BioSphincter
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023